Outcomes among patients with HIV- associated Tuberculosis in Guangxi, People’s Republic of China Zhang Yao, Yu Lan, Ma Ye, Zhao Yan, Sun Kai and Zhang.

Slides:



Advertisements
Similar presentations
When Using DOPPS Slides. DOPPS Slide Use Guidelines.
Advertisements

Tuberculosis incidence and risk factors among adult patients receiving HAART in Senegal: a 7-year cohort study Assane DIOUF et al. IRD/UMR 145 CRCF, CHNU.
Risk factors and true outcomes of children lost to follow-up from antiretroviral therapy in Lilongwe, Malawi C. Ardura Gracia, H. Tweya, C Feldacker, S.
High Rates of Tuberculosis in Patients Accessing HAART in Rural South Africa – Implications for HIV and TB Treatment Programs Kogieleum Naidoo on behalf.
Mortality Among a Tuberculosis Outbreak Los Angeles County, 2007–2013 Brian Baker, MD Amit Chitnis, MD MPH Leslie Henry, BSN RN PHN 48th CTCA Educational.
Antiretroviral therapy eligibility at enrollment and time to treatment initiation in Ethiopia Chloe A. Teasdale 1, Chunhui Wang 1, Sileshi Lulseged 1,
World Health Organization TB Case Definitions
Washington D.C., USA, July 2012www.aids2012.org The value of universal TB screening with GeneXpert MTB/RIF in pre-ART patients in Harare L. Mupfumi.
Most deaths among children enrolled in two program settings in Cambodia occur within the first 6 months after enrolment. Early mortality rates were more.
Characteristics of clients undergoing repeat HIV counseling and testing compared to clients newly-tested for HIV in Nyanza Province Oyaro P, Owuor K, Ng’eno.
Primary Healthcare Facilities Deliver More Effective Antiretroviral Therapy: An Evaluation in Four Provinces in South Africa Geoffrey Fatti, Ashraf Grimwood.
1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.
Decentralization of HIV care and treatment services in Central Province, Kenya: Adult patient characteristics and outcomes Presenting author: William Reidy,
Culture Conversion and Self- Administered Therapy in Privately Managed Tuberculosis Patients Melissa Ehman MPH, Jennifer Flood MD MPH, Pennan Barry MD.
Operational challenge: Linkages from prevention of mother-to-child transmission services to care and treatment services in Zambia S. Okawa,
Figure 1. Number of Tuberculosis Cases: California, California Department of Public Health, Tuberculosis Control Branch Number of Tuberculosis.
Current international guidelines recommend 6–9 months of isoniazid (INH) preventive chemotherapy to prevent the development of active tuberculosis in.
Characteristics and Outcomes of a Population of Tuberculosis Inpatients in Lilongwe, Malawi Mina Hosseinipour, MD, MPH Clinical Director UNC Project Lilongwe,
TB 101: TB Basics and Global Approaches. Objectives Review basic TB facts. Define common TB terms. Describe key global TB prevention and care strategies.
Surveillance to measure impact of ART Theresa Diaz, MD MPH CDC Global AIDS Program.
Morbidity Monitoring Project Data for Resource Planning and Evaluation A.D. McNaghten Centers for Disease Control and Prevention.
Racial Disparities in Antiretroviral Therapy Use and Viral Suppression among Sexually Active HIV-infected Men who have Sex with Men— United States, Medical.
1 Epidemiology of Pediatric Tuberculosis in the United States, 1993–2006 Surveillance, Epidemiology, and Outbreak Investigations Branch Division of Tuberculosis.
Washington D.C., USA, JULY Rulin C. Hechter 1 MD,PhD Jean Q. Wang 1 PhD Margo A. Sidell 1 ScD William J. Towner 2 MD 1 Dept.
Tuberculosis Research of INA-RESPOND on Drug-resistant
Tuberculosis in England 2015 report (presenting data to end of 2014) Tables and figures slide set.
The Immunologic Efficacy of Antiretroviral Therapy among HIV-infected Patients in North America and Africa Elvin Geng* 1, Eric Vittinghoff 1, Jean Nachega.
Management and Development for Health (MDH)
Tuberculosis in the United States National Tuberculosis Surveillance System Highlights from 2011 National Center for HIV/AIDS, Viral Hepatitis, STD, and.
2,500 3,000 3,500 4,000 4,500 5,000 5,500 6,000 2,500 3,000 3,500 4,000 4,500 5,000 5,500 6,000 Figure 1. Number of Tuberculosis Cases: California,
EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.
Neurocognitive Impairment in HIV-Infected Subjects on HAART: Prevalence and Associations Kevin Robertson *1, Kunling Wu 2, Thomas Parsons 1, Ron Ellis.
Implementation of HIV Treatment as Prevention in China Yan Zhao MD National Center for AIDS/STD Control & Prevention Chinese Center for Disease Control.
Engagement in the HIV care cascade among transgender women enrolled in a public HIV clinic in Buenos Aires, Argentina, M.E. Socías 1,2, O. Sued.
Factors Associated with Survival in HIV-Infected African Patients on Antiretroviral Therapy: The Impact of a Sampling-Based Approach to Address Losses.
Beyond Sputum Cups and Four Drugs The Responsibility of the Practicing Clinician in the Community Control of Tuberculosis V. R. Koppaka, MD, PhD Division.
Good Three-year Outcomes of Antiretroviral Therapy at Multiple NGO- assisted facilities in Four Provinces in South Africa Geoffrey Fatti, Ashraf Grimwood.
Retention in Care among HIV-infected Patients Receiving Antiretroviral Therapy in Africa: Estimation via a Sampling-based Approach Elvin Geng 1, David.
TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.
F UNCTIONAL L IMITATIONS IN C ANCER S URVIVORS A MONG E LDERLY M EDICARE B ENEFICIARIES Prachi P. Chavan, MD, MPH Epidemiology PhD Student Xinhua Yu MD.
Outcomes of Antiretroviral Treatment Programs in Rural Lesotho: Health Centers and Hospitals Compared Niklaus Labhardt, Motlalepula Sello, Mamokone A.
Surveillance, Epidemiology, and Outbreak Investigations Branch Division of Tuberculosis Elimination Centers for Disease Control and Prevention (CDC) Epidemiology.
Integration of TB and HIV Screening, Care and Treatment in Mulago Hospital, Uganda Rhoda Wanyenze, Doris Mwesigire, Henry Luzze, Violet Gwokyalya, Julius.
Scale up TB/HIV activities in Asia Pacific 8-9Aug09 1 TB/HIV collaborative activities in Thailand Sriprapa Nateniyom, M.D. TB Bureau, Department of Disease.
Surveillance, Epidemiology, and Outbreak Investigations Branch Division of Tuberculosis Elimination Centers for Disease Control and Prevention (CDC) Epidemiology.
Factors associated with concurrent Heroin use among patients on Methadone maintenance treatment in Vietnam from 2008 to 2013 Hoang Nam Thai MD, MPH – CDC/DGHT.
THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS Yield and impact of repeated screening for tuberculosis and isoniazid preventive therapy among patients.
1 Scaling-up ARV Therapy in Vietnam HAIVN Harvard Medical School AIDS Initiative in Vietnam.
A Call to Action Children – The missing face of AIDS.
A Survival Comparison between HIV+ U.S.-born Latinos and Foreign-born Latinos in Houston, Texas Raouf Arafat, MD, MPH, Adebowale Awosika- Olumo.
Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.
Successfully enrolled in HIV Care but not linked to timely Treatment: Poor retention and Monitoring of Pre-ART patients who are not yet eligible for ART.
Improving Patients Retention in Antiretroviral Treatment Programs: The experience of ARV Programs in Côte d’Ivoire Eugène MESSOU, MD, PhD CePReF- Aconda.
Thailand experience in implementing collaborative HIV/TB activities Anupong Chitwarakorn, MD Ministry of Public Health, Thailand TB/HIV Satellite symposium.
PRESENTED AT THE 9TH IAS CONFERENCE ON HIV SCIENCE - PARIS, FRANCE
I have no conflicts of interest to declare
HIV-1 and STIs Prevalence and Risk Factors among Miners and Female Sex Workers in the Mining Areas of Gejiu, Yunnan, China Ding Guowei, M.D., M.S. National.
Daniel Meressa, M.D. Global Health Committee St. Peter’s Hospital
Tolerability of Isoniazid Preventive Therapy (IPT) in an HIV infected cohort
Tuberculosis in children in Uzbekistan: Don’t forget drug-resistant TB Junia Cajazeiro, Atadjan Khamraev, Philip Du Cros, Tleubergen Abdrasuliev, Joan.
L.F. Jefferys1, J. Hector1, M.A. Hobbins2, J. Ehmer2, N. Anderegg3
Juan Gonzalez Perez AIDS Healthcare Foundation
Dorina Onoya1, Tembeka Sineke1, Alana Brennan1,2, Matt Fox1,2
Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries Kathrin Zürcher, Marie Ballif, Lukas Fenner, Sonia.
Tolerability of Isoniazid Preventive therapy Among HIV infected Cohort in Nigeria Folajinmi Oluwasina Strategic Information Unit AIDS Healthcare Foundation,
24 July 2018 Treatment outcomes with bedaquiline use when substituted for second-line injectables in multidrug resistant tuberculosis: a retrospective.
Management and Development for Health (MDH)
Surveillance for TB in HIV Care and Treatment Settings (CTS)
Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD
Public Health Implications
Presentation transcript:

Outcomes among patients with HIV- associated Tuberculosis in Guangxi, People’s Republic of China Zhang Yao, Yu Lan, Ma Ye, Zhao Yan, Sun Kai and Zhang Fujie Division of Treatment and Care National Center for AIDS/STD Chinese Center of Disease Control and Prevention

Background  TB is the most common co-infection in HIV infected population.  China is a high TB burden country with a growing HIV epidemic.  HIV-associated TB – a particular problem due to its high mortality, diagnostic challenges, and complicated simultaneous treatment of both infections – is therefore a growing concern in China.  Yet outcomes among patients with HIV associated TB in China are not well characterized.

Objective  This study seeks to evaluate the magnitude and determinants of survival among HIV infected patients with culture positive tuberculosis seeking care in the public health system in Guangxi province, China.

Design & Patients  Retrospective cohort study.  Patients were identified from a cross sectional TB screening project during  Adult(>18y) HIV+ patients with a positive TB culture from any body fluid were included and followed until 12 month after TB diagnosis, or death, loss to follow-up, or transfer if earlier.

Study sites Total population: 10 million HIV prevalence: 0.1% TB prevalence in PLWH: 20%

Treatment guidelines  ART starting criteria: changed from CD4<200 to CD4<350 in 2008  ART regimen: AZT(d4T) + 3TC + EFV(NVP)  Timing of ART initiation in ART-Naïve patients with active TB: CD4<200: 2–8 weeks after TB therapy initiation CD4= : after 8 weeks TB induction period CD4>350: after completion of TB therapy  TB regimen: RHZE x 2months then RH x 4months, adjusted according to drug resistance testing

Measurements  Primary outcome of interest: all cause mortality within first 12 months of TB diagnosis.  Clinic records were reviewed at 12 month after the TB diagnosis to ascertain vital status, then confirmed with national HIV database.  Socio-demographic and clinical information were extracted from patients’ charts.  Liquid culture(BacT/Alert) was used for diagnosis and TB drug resistance testing for isoniazid, rifampin, ethambutol, streptomycin.

Statistical analysis  The Kaplan–Meier method was used to estimate the probability of death after TB diagnosis.  Cox regression was used to determine risk factors associated with mortality.  Logistic regression was used to determine factors associated with receipt of TB therapy and ART.

Results-baseline characteristics (n=201) VariableValue Age, years, Median (IQR)37(30-46) Male gender, n (%)163 (81) Transmission Route, n(%) Sex 102 (51) IDU 62 (31) Former plasma donor 3 (2) Unknown 34 (17) History of TB treatment, n(%)13 (7) On ART at TB diagnosis, n(%)69 (34) Baseline CD4, median (IQR)37 (16-101) Extra-pulmonary TB, n(%)111 (55)

Sources of culture samples by location, n(%) Sputum 168 (84) Lymph node aspiration 39 (19) Blood 22 (11) Stool 11 (6) Cerebral Spinal Fluid 7 (4) Pleural fluid 7 (4) Note: some patients had positive cultures from more than one sources.

Drug resistance pattern of 156 M.tuberculosis strains

TB and ARV Treatment Coverage (67%)

Results – 1 year clinical outcomes Total=201 Alive: 123 (61%) Dead: 47 (23%) Transferred: 17 (9%) LTFU: 14 (7%) Accumulative Survival =75% (95%CI, 69-81%)

Risk Factors Associated with Death * Adjusted for gender, age, mode of transmission, CD4 at study entry, extrapulmonary TB, TB drug resistance and ART status at study entry Risk factors UnivariateMultivariate* PvalueHR(95% CI)P valueHR (95% CI) BMI< ( ) ( ) ART during study period < ( ) ( ) TB therapy during study period < ( ) ( ) Cotrimoxazole prophylaxis ( ) ( )

Survival of patients by Treatment status AHR=6; CI [3-13] AHR=7; CI [3-18] AHR=24; CI [9-62] HR=1;ref

Factors associated with death or LTFU variables UnivariateMultivariate* P valueHR (95% CI)P valueHR (95% CI) BMI < ( )< ( ) ART during study period < ( )< ( ) TB Tx during study period < ( ) ( ) Cotrimoxazole prophylaxis < ( ) ( ) * Adjusted for gender, age, mode of transmission, CD4, extrapulmonary TB, TB drug resistance, and ART status on study entry

Factors associated Receiving ARV variables UnivariateMultivariate* P valueOR (95% CI)P valueOR (95% CI) Education (above vs. below middle school) ( ) ( ) Marital status (married vs. not married) ( ) ( ) Received TB Tx ( ) ( ) * Adjusted for gender, age, BMI, mode of transmission, baseline CD4, CXR, and sputum smear

Factors associated with TB Treatment variables UnivariateMultivariate* P valueOR (95% CI)P valueOR (95% CI) CXR (typical vs. others) (1.3-12) ( ) Positive sputum smear (1.0-11) ( ) * Adjusted for gender, age, literacy, marital status, mode of transmission, BMI, baseline CD4, EPTB and sputum smear

Conclusions and implications  This cohort of HIV+ Chinese adults with culture-positive TB demonstrated high tuberculosis drug resistance rate, high 1 year mortality and lower-than-expected treatment coverage.  These findings implicate that strengthening integrated administration of ART and TB therapies are critically important in this setting.

Acknowledgement Sponsors: Clinton Foundation, Global Fund Guangxi Province Health Department: Drs. Liu Wei, Tang Zhirong, Lu Hongyan Liu Zhou CDC: Zheng Yuanjia, MD Naning 4 th Hospital: Huang Shaobiao, MD University of California, San Francisco: Elvin Geng, MD University of North Carolina: Zhu Hao, Ph.D National Institute of Health: Ray Y, Chen, MD University of California, Los anginas : Wen Yi, Ph.D World Health Organization: Fabio Scano Washington University: Maurer Kristin